Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score

Cardiology Journal

Volumn 18, Issue 4, 2011, Pages 364-370

  Che, Jingjin ^a   Li, Guangping ^a   Wang, Weiding ^a   Li, Qiang ^a   Liu, Hongtao ^a   Chen, Kangyin ^a   Liu, Tong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Autoantibodies against human oxidized low density lipoprotein; Coronary heart disease; Gensini score

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; BILIRUBIN GLUCURONIDE; C REACTIVE PROTEIN; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENSINI SCORE; HEART PROTECTION; HOMEOSTATIC MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; MALE; METABOLIC PARAMETERS; PREDICTION; PROTEIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM;

AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHINA; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79960585993     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med, 1999; 340: 115-126.
2. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol, 2006; 6: 508-519.
3. Getz GS, Vanderlaan PA, Reardon CA. The immune system and murine atherosclerosis. Curr Drug Targets, 2007; 8: 1297-1306.
4. Milioti N, Bermudez-Fajardo A, Penichet ML, Oviedo-Orta E. Antigen-induced immunomodulation in the pathogenesis of atherosclerosis. Clin Dev Immunol 2008; 72: 35-39.
5. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development: Clinical and animal studies. Clin Chim Acta, 2004; 348: 1-8.
6. Horkko S, Binder CJ, Shaw PX et al. Immunological responses to oxidized LDL. Free Radic Biol Med, 2000; 28: 1771-1779.
7. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: A role for heat shock proteins in immunisation. Atherosclerosis, 2003; 167: 177-185.
8. Ge J, Jia Q, Liang C et al. Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells. Arterioscler Thromb Vasc Biol, 2005; 25: 2157-2163.
9. Wu R, Shoenfeld Y, Sherer Y et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations:Possible immunomodulation of atherosclerosis. Autoimmunity, 2003; 36: 91-97.
10. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 1992; 339: 883-887.
11. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Morooka S. Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. J Am Coll Cardiol, 2001; 37: 1871-1876.
12. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol, 2001; 21: 108-114.
13. Fredrikson GN, Andersson L, Soderberg I et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity, 2005; 38: 171-179.
14. George J, Afek A, Gilburd B et al. Hyperimmunization of apo-E--deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis, 1998; 138: 147-152.
15. Binder CJ, Hartvigsen K, Chang MK et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest, 2004; 114: 427-437.
16. Fredrikson GN, Soderberg I, Lindholm M et al. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol, 2003; 23: 879-884.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28: 412-419.
18. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem, 1992; 267: 5133-5138.
19. Uusitupa MI, Niskanen L, Luoma J et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol, 1996; 16: 1236-1242.
20. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol, 1983; 51: 606.
21. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res, 2002; 91: 281-291.
22. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med, 2002; 8: 1218-1226.
23. Rossi GP, Cesari M, De Toni R et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation, 2003; 108: 2467-2472.
24. Santos AO, Fonseca FA, Fischer SM et al. High circulating au-toantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta, 2009; 406:113-118.
25. Horkko S, Bird DA, Miller E et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-pro-tein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest, 1999; 103: 117-128.
26. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK. Im-munoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest, 1998; 102: 910-918.
27. Faria-Neto JR, Chyu KY, Li X et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis, 2006; 189: 83-90.
28. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 pep-tide sequences inhibit atherosclerosis. Circulation, 2004; 110: 2047-2052.
29. Schiopu A, Frendeus B, Jansson B et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol, 2007; 50: 2313-2318.
30. Habets KL, van Puijvelde GH, van Duivenvoorde LM et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res, 2010; 85: 622-630.
31. Kara C, Cetinkaya S, Sezgin N, Kinik ST. The effects of metabolic control on oxidized low-density lipoprotein antibodies in children and adolescents with type 1 diabetes mellitus. Pediatr Diab, 2008; 9: 17-22.
32. Garrido-Sanchez L, Garcia-Almeida JM, Garcia-Serrano S et al. Improved carbohydrate metabolism after bariatric surgery raises antioxidized LDL antibody levels in morbidly obese patients. Diabetes Care, 2008; 31: 2258-2264.
33. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia, 2001; 44: 129-146.
34. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in athero-genesis. Free Radic Biol Med, 2000; 28: 1708-1716.
35. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes, 2009; 58: 2711-2717.
36. Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Car-diol, 2000; 36: 1774-1780.
37. Norja S, Nuutila L, Karhunen PJ, Goebeler S. C-reactive protein in vulnerable coronary plaques. J Clin Pathol, 2007; 60: 545-548.
38. Sabatine MS, Morrow DA, Jablonski KA et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 2007; 115: 1528-1536.
39. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipo-protein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res, 2008; 49: 1015-1023.
40. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation, 2001; 103: 1194-1197.
41. Joki N, Hase H, Tanaka Y et al. Relationship between serum albumin level before initiating haemodialysis and angiographic severity of coronary atherosclerosis in end-stage renal disease patients. Nephrol Dial Transplant, 2006; 21: 1633-1639.
42. Narang R, Ridout D, Nonis C, Kooner JS. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol, 1997; 60: 73-79.
43. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation, 2007; 116: 85-97.